# MASLD with Sven Francque - Part 2

Page: https://stenobird.com/podcast/ueg-podcast-6404464/masld-with-sven-francque-part-2
Text version: https://stenobird.com/podcast/ueg-podcast-6404464/masld-with-sven-francque-part-2.md
Podcast: [UEG Podcast](https://stenobird.com/podcast/ueg-podcast-6404464)
Published: 2026-06-02T22:05:00+00:00
Episode link: https://ueg-talks-podcast.podigee.io/77-new-episode
Audio file: https://audio.podigee-cdn.net/2486218-m-71df6806d0c81c8df1c3411d8ce59a5b.mp3?source=feed
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/ueg-podcast-6404464/episodes/masld-with-sven-francque-part-2
Duration seconds: 1685

## Resource

The 2024 MASLD treatment guidelines are already changing. Pradeep Mundre and Professor Sven Francque (Antwerp), guideline co-author, cover weight-loss targets (7% and 10%), resmetirom in F2-F3 fibrosis, semaglutide's positive phase 3 in MASH, plus pioglitazone, bariatric surgery, and liver transplantation in this population.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/ueg-podcast-6404464/episodes/masld-with-sven-francque-part-2/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/ueg-podcast-6404464/masld-with-sven-francque-part-2.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.